BJO

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kon, C. H.
Right arrow Articles by Khaw, P. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kon, C. H.
Right arrow Articles by Khaw, P. T.
Br J Ophthalmol 1998;82:554-560 ( May )

Effects of single, short term exposures of human retinal pigment epithelial cells to thiotepa or 5-fluorouracil: implications for the treatment of proliferative vitreoretinopathy

Chee Hing Kon, Nicholas Laurence Occleston, Alexander Foss, Carl Sheridan, George William Aylward, Peng Tee Khaw

Wound Healing Research Unit, Department of Pathology, Institute of Ophthalmology and Moorfields Eye Hospital, London EC1V 9EL

Correspondence to: Mr C H Kon, Wound Healing Research Unit, Department of Pathology, Institute of Ophthalmology, 11-43 Bath Street, London EC1V 9EL

Accepted for publication 27 November 1997

AIM---To investigate the effects of single, short term (5 or 30 minutes) exposures to thiotepa or 5-fluorouracil (5-FU) on collagen lattice contraction and retinal pigment epithelial (RPE) cell proliferation.
METHODS---For collagen contraction studies, RPE cells seeded into free floating type I collagen lattices were exposed to single 5 or 30 minute treatments with thiotepa (0.06-4 mg/ml), or 5-FU (0.25-25 mg/ml), or phosphate buffered saline alone as a control. For proliferation studies, RPE cell monolayers were similarly exposed to these agents. The degree of contraction, effects on cell number, and viability were determined up to 14 days after treatment.
RESULTS---Contraction of collagen lattices containing RPE cells and proliferation of RPE cells were significantly inhibited (p<0.05) by thiotepa and 5-FU at concentrations above 0.06 mg/ml and 0.25 mg/ml respectively (for both 5 and 30 minute treatments), compared with controls. Cell death did not occur except for exposure of the RPE cells in collagen lattices to the highest concentration of thiotepa (4 mg/ml).
CONCLUSION---It was concluded that single 5 or 30 minute exposures to thiotepa or 5-FU significantly inhibited collagen contraction and the proliferation of RPE cells. These findings suggest that short, single, non-toxic exposures to thiotepa or 5-FU which can be reproduced clinically may be useful in the modulation of proliferative vitreoretinopathy.

Keywords: proliferative vitreoretinopathy; collagen matrix contraction; thiotepa; 5-fluorouracil


© 1998 by British Journal of Ophthalmology



This article has been cited by other articles:


Home page
J. Neurophysiol.Home page
R. L. Spinks, S. N. Baker, A. Jackson, P. T. Khaw, and R. N. Lemon
Problem of Dural Scarring in Recording From Awake, Behaving Monkeys: A Solution Using 5-Fluorouracil
J Neurophysiol, August 1, 2003; 90(2): 1324 - 1332.
[Abstract] [Full Text] [PDF]


Home page
IOVSHome page
K. H. Eibl, B. Banas, C.-L. Schoenfeld, C. A. May, A. S. Neubauer, S. Priglinger, A. Kampik, and U. Welge-Lussen
Alkylphosphocholines Inhibit Proliferation of Human Retinal Pigment Epithelial Cells
Invest. Ophthalmol. Vis. Sci., August 1, 2003; 44(8): 3556 - 3561.
[Abstract] [Full Text] [PDF]


Home page
Br. J. Ophthalmol.Home page
P T Khaw, A D Cambrey, G A Limb, and J T Daniels
Gene therapy: new "magic bullets" to prevent ocular scarring
Br. J. Ophthalmol., May 1, 2002; 86(5): 490 - 492.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 1998 by the BMJ Publishing Group Ltd.